Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of TAK-951 in Healthy Subjects
NCT05567393Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2019
- Primary completion
- Nov 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-951 in nausea ((none)) and Vomiting (18 arms), sponsored by Takeda. Primary endpoints: Percentage of Participants With Clinically Significant Physical Examination Findings up to 32 days, Percentage of Participants With Markedly Abnormal Values of Vital Signs Parameters up to 32 days and 4 more. Started Mar 2019; status: completed.
02
Drugs
TAK-951
03
Conditions
nausea ((none))Vomiting
Beyond the preview
Go deeper on NCT05567393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567393.